First Republic Investment Management, Inc. Reata Pharmaceuticals Inc Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$25.61 - $110.96 $57,545 - $249,327	-2,247 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$100.0 - $143.02 $2,100 - $3,003	-21 Reduced 0.93%	2,247 $226,000
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $8,374 - $16,188	-107 Reduced 4.51%	2,268 $321,000
Q1 2021 May 14, 2021	SELL	$94.25 - $132.81 $4,052 - $5,710	-43 Reduced 1.78%	2,375 $237,000
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $115,702 - $209,359	-1,134 Reduced 31.93%	2,418 $299,000
Q3 2020 Nov 12, 2020	BUY	$93.53 - $163.34 $57,801 - $100,944	618 Added 21.06%	3,552 $346,000
Q2 2020 Aug 13, 2020	BUY	$126.3 - $176.56 $94,346 - $131,890	747 Added 34.16%	2,934 $458,000
Q1 2020 May 13, 2020	SELL	$124.16 - $247.74 $229,571 - $458,071	-1,849 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $137,879 - $402,934	1,849 New	1,849 $378,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account